Overall effect
The 2025 updated meta-analysis of 60 randomized trials reported a small overall standardized mean difference.
Read Scientific Reports ↗RESEARCH NOTES / 001
Interesting is not the same as proven
Curiosity
without
certainty.
Open-label placebo research has produced a real, strange signal. It has not produced permission to claim that a beautiful object treats disease. Here is the evidence—and the guardrail.
01 / PLAIN ENGLISH
A placebo you know is a placebo.
An open-label placebo is an intervention presented honestly as inert. Participants know they are not receiving an active drug. Some randomized trials have still found improvements, particularly in subjective reports such as discomfort, distress, or perceived symptom severity.
That does not mean belief can fix anything. It means experience is partly shaped by expectation, context, learning, attention, and the ritual surrounding an intervention. The machinery is interesting precisely because deception is not required.
Self-reported outcomes
The stronger signal was in what participants reported feeling—not necessarily in objective physiological measures.
Read PubMed record ↗Objective outcomes
Objective outcomes showed a small, nonsignificant estimate. The overall prediction interval also included no effect.
Inspect the analysis ↗Effect sizes are standardized mean differences reported by von Wernsdorff et al., Scientific Reports (2025). An effect size is not a probability that a product will work for an individual.
02 / THE NEGATIVE SPACE
What this does not show.
Not a cure
Subjective symptom change is not tumor shrinkage, restored insulin production, reduced infection, structural healing, or control of a dangerous disease.
Not product proof
Research on a generic placebo, breathing exercise, or ritual does not prove that a finished Mycebo product creates the same result.
Not universal
Effects vary by study, context, outcome, and person. A perfectly valid individual result is: nothing happened.
Not a replacement
A Mycebo object should never be used to delay care, change medication, or override a clinician who knows the actual case.
Not all objective
The best current synthesis found a signal concentrated in self-report. That matters, but it is a narrower claim than “the body heals itself.”
Not settled
Many studies are small; blinding is intrinsically difficult; durability and mechanisms remain uncertain; publication and expectancy biases matter.
The Mycebo claim ceiling
We design salient physical cues and explicit rituals for subjective state transitions. We can describe what an object physically does—blocks light, guides an exhale, marks a choice. We do not claim that it treats anxiety, insomnia, ADHD, depression, pain, or any other condition.
03 / OBJECT-SPECIFIC
Evidence follows the mechanism.
| Object | Physical action we may describe | Evidence bridge | Claim we will not make |
|---|---|---|---|
| The Exhale | Restricts airflow to help pace a longer exhale. | A 2024 meta-analysis of 31 studies found reliable immediate cardiovascular changes from slow-paced breathing; emotional effects were more modest. | “Treats anxiety” or “activates the vagus nerve.” |
| Night Dose | Blocks ambient light and adds gentle distributed weight. | Product testing must verify blackout, comfort, retention, eye clearance, and wash durability. Generic sleep-mask evidence is not product proof. | “Treats insomnia” or “clinically improves sleep.” |
| The Dose | Creates a tactile, visible state-selection cue. | Its useful measure is behavioral: comprehension, repeated use, and whether users report it helped them begin or stop. | “Improves ADHD,” “reduces cortisol,” or “regulates the nervous system.” |
| Expectation Set | Pairs a distinct scent with a chosen repeated ritual. | Fragrance, associative learning, and product-specific user testing can support a ritual story—not a medical one. | “Changes brain chemistry” or “balances mood.” |
| Last Light | Provides a one-button twenty-minute amber fade. | Electrical, optical, thermal, and usability tests establish safety and function. Sleep outcomes require separate testing. | “Corrects circadian rhythm” or “increases melatonin.” |
| Dose Zero | Provides an explicitly inert capsule-taking ritual. | Open-label placebo trials motivate the concept. Written product classification and claims review are required before sale. | Any disease, structure/function, or guaranteed outcome claim. |
04 / ANNOTATED FILE
The reading shelf.
- Effects of open-label placebos across populations and outcomes
Updated systematic review and meta-analysis of 60 randomized trials. The most useful current map of average effect, heterogeneity, and limitations.
Scientific Reports, 2025 ↗ - Placebos without deception in irritable bowel syndrome
The influential 2010 randomized trial that helped establish the modern open-label placebo research program. Promising result; one condition and context, not universal license.
PLOS ONE, 2010 ↗ - Slow-paced breathing: psychophysiological effects
Meta-analysis of 31 studies and 1,133 participants. Supports careful description of immediate effects from slow breathing, while emotional effects were smaller.
Mindfulness, 2024 ↗ - The role of ritual behaviour in anxiety reduction
A 2020 field experiment involving habitual religious ritual. Interesting evidence about ritual context, but not evidence for a Mycebo product.
Philosophical Transactions B, 2020 ↗ - FTC Health Products Compliance Guidance
The practical advertising boundary: the net impression matters; implied health claims count; a tiny disclaimer does not cure a medical headline.
FTC guidance ↗ - A paper we will not cite
The widely repeated 2016 “Rituals Improve Performance by Decreasing Anxiety” article has been retracted over unavailable/anomalous data and unreported exclusions. Convenient evidence is not necessarily sound evidence.
Retraction record ↗
Conclusion / provisional
Use the ritual.
Keep your doctor.
Mycebo is for the territory where an honest cue, a physical action, and some expectation might make experience more workable. Nothing here is medical advice.
See the objects